Enliven Therapeutics, Inc. (ELVN) Dividend History

Company News

• Enliven Therapeutics, Inc. Is a Great Choice for 'Trend' Investors, Here's Why

  Enliven Therapeutics (ELVN) is a good choice for trend investors due to its recent price increase, positive earnings estimate revisions, and strong fundamentals, making it a Zacks Rank #2 (Buy) stock.

  Benzinga
• Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

  Enliven Therapeutics reported positive data from a Phase 1 trial of its drug ELVN-001for chronic myeloid leukemia, with a 44% major molecular response rate by 24 weeks and a favorable safety profile.

  GlobeNewswire Inc.
• Enliven Therapeutics COO sells over $1.25m in company stock - Investing.com

  Anish Patel, the Chief Operating Officer of Enliven Therapeutics, has sold over $1.25 million worth of company stock in a series of transactions. The sales were conducted under a Rule 10b5-1 trading plan, and Patel remains a significant shareholder in the company.

  Investing.com
• 3 Stocks in the Limelight on New Analyst Coverage

  Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Disc Medicine (IRON), Westamerica (WABC) and Enliven (ELVN).

  Zacks Investment Research

  Featured Companies: IRON WABC